Loading...
Header Logo
Keywords
Last Name
Institution

Grant H Skrepnek

TitleProf,Asoc
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPharmacy Clinical & Admin Sci
Phone405/271-6878
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Texas, Austin, TXBSPharmacy
    University of Texas, Austin, TXMScPharmacy
    University of Texas, Austin, TXPhDPharmacy

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Fox AN, Skrepnek GH, Miller JL, Schwier NC, Ripley TL. Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality. Am J Cardiovasc Drugs. 2019 Apr; 19(2):185-193. PMID: 30414088.
      View in: PubMed
    2. Miller JL, Ernst K, Neely SB, Stephens K, Barker P, Skrepnek GH, Johnson PN. Low-dose versus high-dose methadone for the management of neonatal abstinence syndrome. J Opioid Manag. 2019 Mar/Apr; 15(2):159-167. PMID: 31343717.
      View in: PubMed
    3. Pham T, Rathbun RC, Keast S, Nesser N, Farmer K, Skrepnek G. National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. J Eval Clin Pract. 2018 Nov 28. PMID: 30485617.
      View in: PubMed
    4. Tieu JD, Williams RJ, Skrepnek GH, Gentry CA. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther. 2019 Apr; 44(2):220-228. PMID: 30350418.
      View in: PubMed
    5. Combs D, Skrepnek G, Seckeler MD, Barber BJ, Morgan WJ, Parthasarathy S. Sleep-Disordered Breathing is Associated With Increased Mortality in Hospitalized Infants With Congenital Heart Disease. J Clin Sleep Med. 2018 Sep 15; 14(9):1551-1558. PMID: 30176962.
      View in: PubMed
    6. Medina MS, Schwier NC, Miller JL, Miller MM, Skrepnek GH. Career Skills Assessment in a Doctor of Pharmacy Curriculum. Am J Pharm Educ. 2018 09; 82(7):6300. PMID: 30323383.
      View in: PubMed
    7. Pham TT, Skrepnek GH, Bond C, Alfieri T, Cothran TJ, Keast SL. Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016. Med Care. 2018 08; 56(8):727-735. PMID: 29995696.
      View in: PubMed
    8. Keast SL, Holderread B, Cothran T, Skrepnek GH. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost. J Am Pharm Assoc (2003). 2018 Sep - Oct; 58(5):485-491. PMID: 30033127.
      View in: PubMed
    9. Pham TT, Keast SL, Farmer KC, Thompson DM, Rathbun RC, Nesser NJ, Holderread BP, Skrepnek GH. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid. J Manag Care Spec Pharm. 2018 Jul; 24(7):664-676. PMID: 29952711.
      View in: PubMed
    10. Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer. Am J Med. 2018 Oct; 131(10):1187-1199.e5. PMID: 29906429.
      View in: PubMed
    11. Miller JL, Lepa TM, Ranallo C, Chaaban H, Skrepnek GH, Johnson PN. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017 Dec; 18(12):e615-e620. PMID: 29206744.
      View in: PubMed
    12. Tieu JD, Schmidt SA, Miller JL, Kupiec KE, Skrepnek GH, Liu C, Smith WJ. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. J Oncol Pharm Pract. 2019 Apr; 25(3):520-528. PMID: 29157145.
      View in: PubMed
    13. Gentry CA, Giancola SE, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ. A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection. Open Forum Infect Dis. 2017; 4(4):ofx235. PMID: 29255732.
      View in: PubMed
    14. Johnson PN, Skrepnek GH, Golding CL, Owora AH, Thomas AN, Miller JL. Relationship between rate of fentanyl infusion and time to achieve sedation in nonobese and obese critically ill children. Am J Health Syst Pharm. 2017 Aug 01; 74(15):1174-1183. PMID: 28588011.
      View in: PubMed
    15. Skrepnek GH, Mills JL, Lavery LA, Armstrong DG. Health Care Service and Outcomes Among an Estimated 6.7 Million Ambulatory Care Diabetic Foot Cases in the U.S. Diabetes Care. 2017 07; 40(7):936-942. PMID: 28495903.
      View in: PubMed
    16. Scalese MJ, Herring HR, Rathbun RC, Skrepnek GH, Ripley TL. Propofol-associated QTc prolongation. Ther Adv Drug Saf. 2016 Jun; 7(3):68-78. PMID: 27298717.
      View in: PubMed
    17. Keast SL, Skrepnek G, Nesser N. State Medicaid Programs Bring Managed Care Tenets to Fee for Service. J Manag Care Spec Pharm. 2016 Feb; 22(2):145-8. PMID: 27015253.
      View in: PubMed
    18. Altyar A, Kordi L, Skrepnek G. Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA. BMJ Open. 2015 Sep 09; 5(9):e007368. PMID: 26353865.
      View in: PubMed
    19. Skrepnek GH, Mills JL, Armstrong DG. A Diabetic Emergency One Million Feet Long: Disparities and Burdens of Illness among Diabetic Foot Ulcer Cases within Emergency Departments in the United States, 2006-2010. PLoS One. 2015; 10(8):e0134914. PMID: 26248037.
      View in: PubMed
    20. Altyar A, Bakhsh HT, Mohammed A, Skrepnek G, Patanwala AE. Administration of first dose antibiotic in the ED in patients with minor skin and soft tissue infections. Am J Emerg Med. 2015 Sep; 33(9):1225-8. PMID: 26070237.
      View in: PubMed
    21. Skrepnek GH, Mills JL, Armstrong DG. Foot-in-wallet disease: tripped up by "cost-saving" reductions? Diabetes Care. 2014 Sep; 37(9):e196-7. PMID: 25147261.
      View in: PubMed
    22. Sun D, Abraham I, Slack M, Skrepnek GH. Emergency department visits in the United States for pediatric depression: estimates of charges and hospitalization. Acad Emerg Med. 2014 Sep; 21(9):1003-14. PMID: 25269581.
      View in: PubMed
    23. Skrepnek GH, Armstrong DG, Mills JL. Open bypass and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010. J Vasc Surg. 2014 Nov; 60(5):1255-1265. PMID: 25017514.
      View in: PubMed
    24. Tate WR, Skrepnek GH. Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer. Psychooncology. 2015 Mar; 24(3):253-61. PMID: 24917078.
      View in: PubMed
    25. Gilligan AM, Skrepnek GH. Determinants of life expectancy in the Eastern Mediterranean Region. Health Policy Plan. 2015 Jun; 30(5):624-37. PMID: 24920217.
      View in: PubMed
    26. Armstrong EP, Bakall M, Skrepnek GH, Boyer LV. Is scorpion antivenom cost-effective as marketed in the United States? Toxicon. 2013 Dec 15; 76:394-8. PMID: 24055550.
      View in: PubMed
    27. Skrepnek GH, Tate WR, Baker AF. Clinical and economic burden of Richter syndrome in inpatient cases of chronic lymphocytic leukemia within the United States, 2001-2010. Leuk Lymphoma. 2014 Apr; 55(4):834-40. PMID: 23772638.
      View in: PubMed
    28. Barnes CJ, Caon C, Foley JF, Friedman M, Menzin J, Nair KV, Nichols C, Olvey EL, Owens GM, Pill MW, Skrepnek GH, White LA, Zerkowski K. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S1-53. PMID: 23383730.
      View in: PubMed
    29. Owens GM, Olvey EL, Skrepnek GH, Pill MW. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S41-53. PMID: 23383732.
      View in: PubMed
    30. Tang DH, Alberts DS, Nevins R, Sullivan S, Skrepnek GH. Health care expenditures, hospitalizations, and productivity associated with cancer in US employer settings. J Occup Environ Med. 2012 Dec; 54(12):1453-60. PMID: 23169275.
      View in: PubMed
    31. Gilligan AM, Skrepnek GH. An analysis of security price risk and return among publicly traded pharmacy corporations. Res Social Adm Pharm. 2013 Nov-Dec; 9(6):828-40. PMID: 23084271.
      View in: PubMed
    32. Amini A, Patanwala AE, Maegawa FB, Skrepnek GH, Jie T, Gruessner RW, Ong ES. Effect of epidural analgesia on postoperative complications following pancreaticoduodenectomy. Am J Surg. 2012 Dec; 204(6):1000-4; discussion 1004-6. PMID: 23022251.
      View in: PubMed
    33. Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. J Med Econ. 2013; 16(1):10-8. PMID: 22947171.
      View in: PubMed
    34. Jasiak KD, Phan H, Christich AC, Edwards CJ, Skrepnek GH, Patanwala AE. Induction dose of propofol for pediatric patients undergoing procedural sedation in the emergency department. Pediatr Emerg Care. 2012 May; 28(5):440-2. PMID: 22531193.
      View in: PubMed
    35. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012 Apr; 9(2):131-41. PMID: 22409371.
      View in: PubMed
    36. Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay JW. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent. 2010 Nov-Dec; 58(6):484-92; quiz 493-4. PMID: 21062718.
      View in: PubMed
    37. Hess LM, Malone DC, Skrepnek GH, Reed PG, Armstrong E, Coons SJ. Oncologist preferences for health states associated with the treatment of advanced ovarian cancer. Appl Health Econ Health Policy. 2010; 8(4):217-23. PMID: 20578777.
      View in: PubMed
    38. Murphy JE, Malone DC, Olson BM, Grizzle AJ, Armstrong EP, Skrepnek GH. Development of computerized alerts with management strategies for 25 serious drug-drug interactions. Am J Health Syst Pharm. 2009 Jan 01; 66(1):38-44. PMID: 19106343.
      View in: PubMed
    39. Olvey EL, Skrepnek GH. The cost-effectiveness of sertraline in the treatment of depression. Expert Opin Pharmacother. 2008 Oct; 9(14):2497-508. PMID: 18778187.
      View in: PubMed
    40. Mahmood MH, Armstrong EP, Malone DC, Skrepnek GH. Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centers. Am J Health Syst Pharm. 2008 Sep 15; 65(18):1744-9. PMID: 18769002.
      View in: PubMed
    41. Ko Y, Malone DC, D'Agostino JV, Skrepnek GH, Armstrong EP, Brown M, Woosley RL. Potential determinants of prescribers' drug-drug interaction knowledge. Res Social Adm Pharm. 2008 Dec; 4(4):355-66. PMID: 19064242.
      View in: PubMed
    42. Olvey EL, Skrepnek GH, Nolan PE. Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model. Am J Health Syst Pharm. 2008 Aug 01; 65(15):1435-42. PMID: 18653814.
      View in: PubMed
    43. Wang MT, Skrepnek GH, Armstrong E, Sherrill DL, Harris RB, Tsai CL, Malone DC. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Curr Med Res Opin. 2008 Mar; 24(3):859-67. PMID: 18267052.
      View in: PubMed
    44. Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, Abarca J, Rehfeld RA, Reel SJ, Woosley RL. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf. 2008; 31(6):525-36. PMID: 18484786.
      View in: PubMed
    45. Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH, Jones WN, Schepers GP, Nichol WP, Houranieh A, Dare DC, Hoey CT, Malone DC. Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care. 2007 Oct; 13(10):573-8. PMID: 17927462.
      View in: PubMed
    46. Mahmood M, Malone DC, Skrepnek GH, Abarca J, Armstrong EP, Murphy JE, Grizzle AJ, Ko Y, Woosley RL. Potential drug-drug interactions within Veterans Affairs medical centers. Am J Health Syst Pharm. 2007 Jul 15; 64(14):1500-5. PMID: 17617500.
      View in: PubMed
    47. Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007 Jun; 27(6):813-24. PMID: 17542764.
      View in: PubMed
    48. Malone DC, Abarca J, Skrepnek GH, Murphy JE, Armstrong EP, Grizzle AJ, Rehfeld RA, Woosley RL. Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Med Care. 2007 May; 45(5):456-62. PMID: 17446832.
      View in: PubMed
    49. Plaza CM, Draugalis JR, Slack MK, Skrepnek GH, Sauer KA. Curriculum mapping in program assessment and evaluation. Am J Pharm Educ. 2007 Apr 15; 71(2):20. PMID: 17533429.
      View in: PubMed
    50. Plaza CM, Draugalis JR, Slack MK, Skrepnek GH, Sauer KA. Use of reflective portfolios in health sciences education. Am J Pharm Educ. 2007 Apr 15; 71(2):34. PMID: 17533443.
      View in: PubMed
    51. Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin. 2007 Feb; 23(2):245-50. PMID: 17288677.
      View in: PubMed
    52. Armstrong EP, Skrepnek GH, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2007 Feb; 23(2):251-8. PMID: 17288678.
      View in: PubMed
    53. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007 Jan-Feb; 20(1):72-80. PMID: 17204738.
      View in: PubMed
    54. Skrepnek GH. The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis. Pharmacoeconomics. 2007; 25(8):649-64. PMID: 17640107.
      View in: PubMed
    55. Abarca J, Malone DC, Skrepnek GH, Rehfeld RA, Murphy JE, Grizzle AJ, Armstrong EP, Woosley RL. Community pharmacy managers' perception of computerized drug-drug interaction alerts. J Am Pharm Assoc (2003). 2006 Mar-Apr; 46(2):148-53. PMID: 16602224.
      View in: PubMed
    56. Skrepnek GH, Armstrong EP, Malone DC, Abarca J, Murphy JE, Grizzle AJ, Rehfeld RA, Woosley RL. Workload and availability of technology in metropolitan community pharmacies. J Am Pharm Assoc (2003). 2006 Mar-Apr; 46(2):154-60. PMID: 16602225.
      View in: PubMed
    57. Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. Ann Pharmacother. 2005 Nov; 39(11):1785-91. PMID: 16219900.
      View in: PubMed
    58. Skrepnek GH. Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Rev Pharmacoecon Outcomes Res. 2005 Oct; 5(5):603-23. PMID: 19807587.
      View in: PubMed
    59. Skrepnek GH. Regression methods in the empiric analysis of health care data. J Manag Care Pharm. 2005 Apr; 11(3):240-51. PMID: 15804208.
      View in: PubMed
    60. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005 Mar; 25(3):325-34. PMID: 15843279.
      View in: PubMed
    61. Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. Curr Med Res Opin. 2005 Feb; 21(2):261-70. PMID: 15801997.
      View in: PubMed
    62. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care. 2004 Jul; 10(5 Suppl):S129-38. PMID: 15354678.
      View in: PubMed
    63. Skrepnek GH, Skrepnek SV. An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma. Am J Manag Care. 2004 Jul; 10(5 Suppl):S139-52. PMID: 15354679.
      View in: PubMed
    64. Skrepnek GH. Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry. Clin Ther. 2004 Jan; 26(1):155-74. PMID: 14996527.
      View in: PubMed
    65. Lai LK, Armstrong EP, Salcido AL, French R, Skrepnek GH. Women's perception of bone-mineral density testing and osteoporosis education in the community pharmacy. Consult Pharm. 2003 Nov; 18(11):968-76. PMID: 16563068.
      View in: PubMed
    Skrepnek's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description